Exelixis has filed its next-generation therapy zanzalintinib with U.S. regulators for metastatic colorectal cancer, marking a significant step in its clinical development and potentially enhancing its competitive position in the targeted oncology space.
Idorsia's exclusive licensing agreement with EMS to commercialize insomnia drug QUVIVIQ across Latin America marks a key step in its global expansion. The deal, involving $20 million in milestones and royalties, arrives as long-term data for its Fabry disease candidate lucerastat puts the spotlight on the company's broader late-stage pipeline and persistent financial pressures.
Amid a steep 60% annual share price decline, investment firm Chicago Capital has significantly reduced its position in PROCEPT BioRobotics, a developer of robotic systems for urological surgery, signaling a portfolio risk reassessment.
In a rare firsthand account, Dr. Mohamed Ibrahim details his three-day escape from el-Fasher as paramilitary forces overran the city. His testimony paints a harrowing picture of urban warfare, civilian slaughter, and the systematic collapse of Sudan's last army bastion in Darfur.
Danaher Corporation announces a strategic investment in Automata, aiming to integrate AI-ready automation systems with its extensive portfolio of instruments and reagents. The move signals a push to deliver comprehensive, data-driven lab solutions as the life sciences sector increasingly prioritizes efficiency and scalability.
After a bruising year that saw its shares tumble by a third, biotech giant CSL is back in the spotlight. We delve beyond the headline numbers, examining valuation models and market sentiment to assess if the sell-off has created a compelling entry point for long-term investors.
A devastating landslide at the Rubaya coltan mine in eastern DRC has claimed hundreds of lives, casting a harsh spotlight on the perilous conditions in artisanal mining and the complex conflict over the region's critical minerals.
Galderma Group's (SWX:GALD) shares have faced significant pressure in recent months, contrasting sharply with its strong yearly performance. This analysis delves into whether the current valuation presents a genuine entry point or reflects deeper concerns about the dermatology giant's ambitious growth narrative.
In a significant move to bolster its healthcare services and retain staff, Walmart is creating thousands of new leadership positions and raising wages for pharmacy technicians across its U.S. stores.
Medtronic's expanded partnership with Mindray integrates its monitoring technologies into ASC-focused platforms, a strategic move to embed itself in a high-growth segment while analysts debate its impact on the broader investment thesis.
Facing softer demand and tariff volatility, Minerals Technologies (MTX) reported steady 2025 sales of $2.1B but saw margins contract. Leadership emphasized cost discipline and safety while detailing a series of expansion projects poised to drive a meaningful rebound in the coming year.
Chemical and ammunition manufacturer Olin Corporation reported fourth-quarter results that missed internal forecasts, pressured by plant disruptions, supply issues, and a sharp year-end drop in chlorine demand. Executives emphasized cash preservation and cost control while navigating what they term an extended market downturn.
The Hartford Financial Services Group reported robust fourth-quarter and full-year 2025 results, driven by profitable underwriting growth, higher investment income, and disciplined capital management. CEO Chris Swift outlined a strategic shift towards an "AI-first" operational model while signaling confidence in sustained margins and growth across business and personal lines.
Novo Nordisk's newly launched oral GLP-1 drug, amycretin, has seen explosive initial demand in the U.S., potentially setting the stage for a significant financial turnaround and stock rally after a challenging previous year.
Shares of Spanish dermatology specialist Almirall (BME:ALM) present a conundrum for investors. While recent trading has been volatile, a key valuation model suggests the stock is trading at a 7.8% discount to its estimated fair value. We examine the bullish case built on its pipeline, the risks it faces, and what the significant gap between its current and forward P/E ratios might signal.
Stryker Corporation's latest earnings report, driven by its MedSurg, Neurotechnology divisions and the Mako surgical robot, has reignited investor debate. With shares near $370 and a bullish fair value estimate of $427, analysts are weighing robust growth against a premium valuation.
Merck & Co. shifts its cancer drug development playbook, opting for targeted collaborations with Guardant Health and Eikon Therapeutics after walking away from a major acquisition. Analysts debate whether the stock's current price fully reflects its long-term pipeline potential.
The FDA's Priority Review for Vyvgart's label expansion in myasthenia gravis accelerates Argenx's growth strategy, while investors weigh the company's broader pipeline against its current valuation.
Citi analyst Geoff Meacham raised his price target on Bristol-Myers Squibb (BMY) to $60, citing a more favorable setup for the sector. The move comes as the drugmaker also announces a partnership with Microsoft to leverage AI for earlier lung cancer detection.
While fully autonomous robotic surgeons remain on the horizon, the foundational technology and data ecosystems being built today are setting the stage for a transformative shift. Two industry giants, Intuitive Surgical and Medtronic, offer investors distinct pathways to capitalize on this evolving landscape.
